Future perspectives in melanoma research. Meeting report from the "Melanoma Research: a bridge Naples-USA. Naples, December 6th-7th2010"

Journal of Translational Medicine

Review

Frederic F Lehmann¹  Mohamed Kashani-sabet²  Claudio Dansky Ullmann³  Alistair Cochran⁴  Ruth Halaban⁵  John M Kirkwood⁶  Antoni Ribas⁷  Peter P Lee⁸  Eleonora De Maio⁹  Paolo A Ascierto⁹  Nicola Mozzillo⁹  Douglas J Schwartzentruber^1,10  David F Stroncek^1,11  Franco M Marincola^1,11  Ena Wang^1,11  Jerome Galon^1,12  Bernard A Fox^1,13  Keith Flaherty^1,14  Michele Maio^1,15  Stefano Bertuzzi^1,16  Mary Hendrix^1,17  James Yang^1,18  Giuseppe Palmieri^1,19  Licia Rivoltini^2,20  Soldano Ferrone^2,21  Mario Sznol^2,22 

[1] Cancer Immunotherapeutics Business Unit, GlaxoSmithKline Biologicals, Rixensart, Belgium;Center for Melanoma Research and Treatment, California Pacific Medical Center Research Institute, San Francisco, CA, USA;Clinical Investigations Branch, Cancer Therapy Evaluation Program DCTD, National Cancer Institute, Bethesda, MD, USA;David Geffen School of Medicine at UCLA, Los Angeles, CA, USA;Department of Dermatology, Yale University School of Medicine, New Haven, CT, USA;Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Cancer Institute, and Melanoma Program, Pittsburgh Cancer Institute, Pittsburgh, PA, USA;Department of Medicine, Jonsson Comprehensive Cancer Center, UCLA, Los Angeles, California, USA;Department of Medicine, Stanford University, Stanford, CA, USA;Department of Melanoma, Sarcoma, and Head and Neck Disease, Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy;Indiana University Health Goshen Center for Cancer Care, Goshen, IN, USA;Infectious Diseases and Immunogenetics Section (IDIS), Department of Transfusion Medicine, Clinical Center and Center for Human Immunology (CHI), NIH, Bethesda, Maryland, USA;Inserm Group Leader, Inserm U872, Team 15, Cordeliers Research Center, Paris, France;Laboratory of Molecular and Tumor Immunology, Robert W. Franz Cancer Research Center, Earle A. Chiles Research Institute, Providence Portland Medical Center, Portland, Oregon, USA;Department of Molecular Microbiology and Immunology, Oregon Health and Science University, Portland, Oregon, USA;Massachusetts General Hospital Cancer Center, Boston, MA, USA;Medical Oncology and Immunotherapy, Department of Oncology, University, Hospital of Siena, Istituto Toscano Tumori, Siena, Italy;Office of the Director, Office of Science Policy Analysis, Office of Science Policy, National Institutes of Health, Bethesda, MD, USA;Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA;Surgical Brach, NIH, Bethesda, MA, USA;Unit of Cancer Genetics, Institute of Biomolecular Chemistry, National Research Council (CNR), Sassari, Italy;Unit of Immunotherapy of Human Tumors, IRCCS Foundation, Istituto Nazionale Tumori, Milan, Italy;University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA;Yale Cancer Center, New Haven, CT, USA;

关键词: Melanoma;    Metastatic Melanoma;    Melanoma Patient;    Dasatinib;    Ipilimumab;   

DOI  :  10.1186/1479-5876-9-32

 received in 2011-03-14, accepted in 2011-03-26,  发布年份 2011

来源: Springer

【 摘 要 】

Progress in understanding the molecular basis of melanoma has made possible the identification of molecular targets with important implications in clinical practice. In fact, new therapeutic approaches are emerging from basic science and it will be important to implement their rapid translation into clinical practice by active clinical investigation.The first meeting of Melanoma Research: a bridge Naples-USA, organized by Paolo A. Ascierto (INT, Naples, Italy) and Francesco Marincola (NIH, Bethesda, USA) took place in Naples, on 6-7 December 2010.This international congress gathered more than 30 international and Italian faculty members and was focused on recent advances in melanoma molecular biology, immunology and therapy, and created an interactive discussion across Institutions belonging to Government, Academy and Pharmaceutical Industry, in order to stimulate new approaches in basic, translational and clinical research. Four topics of discussion were identified: New pathways in Melanoma, Biomarkers, Clinical Trials and New Molecules and Strategies.

【 授权许可】

CC BY   
© Ascierto et al; licensee BioMed Central Ltd. 2011